𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Drug action on ribonucleotide reductase

✍ Scribed by Joseph G. Cory; Gay L. Carter

Book ID
118372034
Publisher
Elsevier Science
Year
1985
Tongue
English
Weight
891 KB
Volume
24
Category
Article
ISSN
0065-2571

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mechanism for ribonucleotide reductase i
Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine
✍ Susana Pereira; Pedro Alexandrino Fernandes; Maria JoΓ£o Ramos πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 147 KB

## Abstract Gemcitabine (2β€²,2′‐difluoro‐2′‐deoxycytidine, dFdC) is a very promising anticancer drug, already approved for clinical use in three therapeutic indications. It is metabolized intracellularly to 5′‐diphosphate (dFdCDP), which is known to be a potent inhibitor of ribonucleotide reductase

Mechanisms of action of peptide inhibito
Mechanisms of action of peptide inhibitors of mammalian ribonucleotide reductase targeting quaternary structure
✍ Ying Gao; Ossama B. Kashlan; Jaskiran Kaur; Chiheng Tan; Barry S. Cooperman πŸ“‚ Article πŸ“… 2005 πŸ› Wiley (John Wiley & Sons) 🌐 English βš– 203 KB

Mammalian ribonucleotide reductase (mRR) is a chemotherapeutic target. The enzyme is composed of 2 subunits (mR1 and mR2) and is inhibited by Ac-FTLDADF (denoted P7), corresponding to the C-terminus of mR2, which competes with mR2 for binding to mR1. mRR has 2 physiologically important active forms,